

ENANTA PHARMACEUTICALS INC  
Form 8-K  
January 06, 2017

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): January 6, 2017**

**ENANTA PHARMACEUTICALS, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**

**of incorporation)**

**001-35839**  
**(Commission**

**File Number)**

**500 Arsenal Street, Watertown, Massachusetts 02472**

**04-3205099**  
**(IRS Employer**

**Identification No.)**

Edgar Filing: ENANTA PHARMACEUTICALS INC - Form 8-K

**(Address of principal executive offices and zip code)**

**(617) 607-0800**

**(Registrant's telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(e) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01 Regulation FD Disclosure.**

On January 6, 2017, Enanta Pharmaceuticals, Inc. provided via press release highlights of its business overview and update on its research and development programs. A copy of Enanta's press release is hereby furnished to the Commission as Exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

**Exhibit**

| <b>No.</b> | <b>Description</b>  |
|------------|---|
| 99.1       | Press Release of Enanta Pharmaceuticals, Inc. dated January 6, 2017, announcing highlights of business overview and update on its research and development programs to be presented at the 35 <sup>th</sup> Annual J.P. Morgan Healthcare Conference. |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 6, 2017

ENANTA PHARMACEUTICALS, INC.

/s/ Paul J. Mellett  
Paul J. Mellett  
Senior Vice President, Finance and Administration and  
Chief Financial Officer

**EXHIBIT INDEX**

**Exhibit**

| <b>No.</b> | <b>Description</b>   |
|------------|--|
| 99.1       | Press Release of Enanta Pharmaceuticals, Inc., dated January 6, 2017, announcing highlights of business overview and update on its research and development programs to be presented at the 35 <sup>th</sup> Annual J.P. Morgan Healthcare Conference. |